Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-Resistant (CRE) of Various Carbapenemase Phenotypes in Southwestern China.

BACKGROUND

Carbapenem-resistant Enterobacteriaceae (CRE) presents a significant challenge due to its role in severe and multidrug-resistant infections.

PURPOSE

This study aims to evaluate aztreonam (ATM) as a synergistic agent with ceftazidime/avibactam (CZA) for treating CRE strains with different carbapenemase phenotypes.

METHODS

A total of 87 non-repeated clinical CRE strains were collected from various clinical specimens at The First Affiliated Hospital of Guangxi Medical University. Carbapenemase genotypes and phenotypes were identified using polymerase chain reaction (PCR) and NG-Test Carba 5 methods. The synergistic effect of CZA combined with ATM was assessed via the checkerboard MIC and disk stacking methods.

RESULTS

The clinical analysis revealed that underlying pulmonary disease, pneumonia, urinary catheter, and central intravenous catheter were associated with poor prognosis in CRE infections (p<0.05). All 87 CRE strains showed high resistance to most antibiotics, especially cefazolin, ceftriaxone, piperacillin/tazobactam, ertapenem, and meropenem, with a rate of 100.00%. For strains with a single carbapenemase gene, NG-Test Carba 5 demonstrated 100.00% accuracy. Notably, The combination of CZA and ATM showed synergy in 95.40% (83/87) of the CRE strains overall, with specific rates of 100.00% (4/4) in strains lacking detectable carbapenemase genes, 94.29% (33/35) in those with , and 100.00% (3/3) in those with plus or plus .

CONCLUSION

In conclusion, ATM significantly enhances CZA's activity against CRE strains in Guangxi, achieving a high synergy rate across diverse isolates, regardless of the carbapenemase genes present.